Johnson & Johnson $JNJ Stock Position Raised by Hudson Value Partners LLC

Hudson Value Partners LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 8.5% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 38,698 shares of the company’s stock after purchasing an additional 3,045 shares during the period. Johnson & Johnson makes up about 2.5% of Hudson Value Partners LLC’s holdings, making the stock its 10th biggest position. Hudson Value Partners LLC’s holdings in Johnson & Johnson were worth $9,828,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of JNJ. Sierra Capital LLC raised its position in Johnson & Johnson by 0.5% in the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after acquiring an additional 41 shares in the last quarter. Beaird Harris Wealth Management LLC lifted its holdings in Johnson & Johnson by 1.8% in the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock valued at $501,000 after acquiring an additional 42 shares during the period. Ballast Advisors LLC boosted its position in shares of Johnson & Johnson by 1.2% during the 1st quarter. Ballast Advisors LLC now owns 3,598 shares of the company’s stock worth $879,000 after purchasing an additional 42 shares in the last quarter. Broadleaf Partners LLC grew its stake in shares of Johnson & Johnson by 0.6% during the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock worth $1,521,000 after purchasing an additional 43 shares during the period. Finally, Jessup Wealth Management Inc increased its holdings in shares of Johnson & Johnson by 0.6% in the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock valued at $1,567,000 after purchasing an additional 44 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $259.28 on Wednesday. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average price is $249.94 and its 200 day moving average price is $240.47. Johnson & Johnson has a 52 week low of $171.81 and a 52 week high of $274.90. The stock has a market cap of $624.84 billion, a price-to-earnings ratio of 30.04, a PEG ratio of 2.50 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 annualized dividend and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.11%.

Analyst Upgrades and Downgrades

Several analysts recently commented on JNJ shares. Leerink Partners upgraded shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research note on Wednesday, May 13th. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research report on Monday, August 3rd. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Scotiabank reissued an “outperform” rating and set a $305.00 price target on shares of Johnson & Johnson in a research note on Thursday, July 16th. Finally, Barclays upped their price target on Johnson & Johnson from $234.00 to $255.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $268.22.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s fiscal second-quarter results exceeded expectations, with revenue rising 6.6% year over year to $25.31 billion and adjusted earnings per share reaching $2.90. The company also raised or reaffirmed its full-year outlook, reinforcing confidence in operating momentum. Johnson & Johnson vs. Medtronic
• Positive Sentiment: The FDA granted De Novo authorization for J&J’s OTTAVA soft-tissue robotic surgery system, giving its MedTech business an entry point into a growing market and potentially creating a new source of long-term growth. OTTAVA FDA approval
• Positive Sentiment: Additional growth initiatives include a preferred cardiac electrophysiology technology agreement with ACCESS for ambulatory surgery centers, a priority review for RYBREVANT FASPRO, and a collaboration focused on in vivo CAR-T therapies. ACCESS strategic agreement
• Neutral Sentiment: Analysts and commentators generally view JNJ as a hold or moderate buy. Shares are trading above their 50-day and 200-day moving averages, but the stock’s strong rally leaves less valuation support; investors are weighing its roughly 30 times earnings multiple against future growth. JNJ nearing its 52-week high
• Negative Sentiment: Patent expirations, MedTech competition, pipeline execution risks and ongoing talc litigation remain important overhangs. J&J’s proposed $5.5 billion talc settlement framework could reduce legal uncertainty, but it also highlights the potential for substantial cash costs and continued investor scrutiny. OTTAVA FDA win and talc deal

Insider Transactions at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 48,972 shares of company stock valued at $12,295,205 over the last three months. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.